Linifanib is a type I tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by linifanib (Hernandez-Davies et al, 2011; Nguyen et al, 2017).
Hernandez-Davies, JE, Zape, JP, Landaw, EM, Tan, X, Presnell, A, Griffith, D, Heinrich, MC, Glaser, KB, Sakamoto, KM
Nguyen, B, Williams, AB, Young, DJ, Ma, H, Li, L, Levis, M, Brown, P, Small, D
© 2021 Reactome